Company intelligence / Profile preview
Editas Medicine
Cambridge, MA, United Stateseditasmedicine.com ↗
- Ownership
- Public · EDIT
- Employees
- ~80
- Development stage
- Phase 1
01
Overview
Editas Medicine is a pioneering clinical-stage biotechnology company developing transformative genomic medicines using CRISPR-based gene editing technologies. The company has demonstrated preclinical proof-of-concept for in vivo HBG1/2 promoter editing to induce fetal hemoglobin for sickle cell disease and beta-thalassemia using lipid nanoparticle delivery systems. Its previous ex vivo program reni-cel was discontinued at the end of 2024 due to lack of commercial partnership.[9] The company aims to achieve human proof-of-concept with its new in vivo pipeline within two years.[9] Clinical results from earlier programs showed safety and some efficacy signals but the company's strategic focus is now on next-generation in vivo approaches.
- Therapeutic areas
- OphthalmologyHematologyOncologyRare Diseases
- Modalities
- CRISPR-based gene editing (CRISPR/Cas9 and CRISPR/Cas12a)In vivo gene editingCell therapy assets in oncology
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Bristol Myers Squibb – oncology/cellular therapiesImmatics N.V. – gamma-delta T-cell therapiesGenevant Sciences – LNP delivery technology collaboration for mRNA/gene-editing therapeutics ($283M deal)Vertex Pharmaceuticals – licensing deal ($100M upfront payment)DRI Healthcare subsidiary – revenue trading agreement related to Vertex license ($57M payment)
04
Financials
- Market cap
- $425.1M
- Total revenue
- $11.9M
- Enterprise value
- $229M
Beyond the preview
Go deeper on Editas Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Editas Medicine.